Revive Therapeutics 

$0.012600
47
+$0.00+5%Friday 20:41

Statistics

Day High
0.0112
Day Low
0.011
52W High
0.052
52W Low
0.007
Volume
160,080
Avg. Volume
186,975
Mkt Cap
5.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Oct 27Expected
Q3 2020
Q4 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-0.02
-0.02
-0.01
-0
Expected EPS
N/A
Actual EPS
-0.0039

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.06MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVVTF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.
Show More
CEO
Michael Frank
Employees
2
Country
Canada
ISIN
CA7615161030
WKN
000A2AP4F

Listings

0 Comments

Share your thoughts

FAQs

What is Revive Therapeutics stock price today?▼
The current price of RVVTF is $0.01 USD — it has increased by +5% in the past 24 hours. Watch Revive Therapeutics stock price performance more closely on the chart.
What is Revive Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Revive Therapeutics stocks are traded under the ticker RVVTF.
Is Revive Therapeutics stock price growing?▼
RVVTF stock has fallen by -3.08% compared to the previous week, the month change is a -33.68% fall, over the last year Revive Therapeutics has showed a +80% increase.
What is Revive Therapeutics market cap?▼
Today Revive Therapeutics has the market capitalization of 5.49M
What were Revive Therapeutics earnings last quarter?▼
RVVTF earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Revive Therapeutics revenue for the last year?▼
Revive Therapeutics revenue for the last year amounts to 0 USD.
What is Revive Therapeutics net income for the last year?▼
RVVTF net income for the last year is -8.06M USD.
How many employees does Revive Therapeutics have?▼
As of November 16, 2026, the company has 2 employees.
In which sector is Revive Therapeutics located?▼
Revive Therapeutics operates in the Health & Wellness sector.
When did Revive Therapeutics complete a stock split?▼
Revive Therapeutics has not had any recent stock splits.
Where is Revive Therapeutics headquartered?▼
Revive Therapeutics is headquartered in Toronto, Canada.